Efficacy of Myo-inositol on Anthropometric, Metabolic, and Endocrine Outcomes in PCOS Patients: a Meta-analysis of Randomized Controlled Trial

A Literature Review and a Proposed Classification of the Relationships between Ovulatory Infertility and Lifestyle Factors Based on the Three Groups of Ovulation Disorders Classified by WHO

“…Another meta-analysis noted an influence of MI on the levels of SHBG, androstenedione, prolactin, and total testosterone in patients with PCOS [137]. In addition, a meta-analysis performed by Jethaliy et al showed a significant influence of MI on the levels of androstenedione and prolactin only [138]. Meta-analyses performed by Zeng and Facchinetti et al, on the other hand, did not show a significant improvement in endocrine parameters such as the testosterone level [139,140].…”

“…Moreover, several meta-analyses showed improvements in glycemic parameters such as the fasting glucose concentration, fasting insulin concentration, glucose/insulin ratio, and HOMA after treatment with MI in patients with PCOS [136,137,139,140,[142][143][144]. However, two other meta-analyses did not indicate an improvement in any of the aforementioned glycemic parameters in women with PCOS [5,138]. What is more, although inositol has been proposed as a possible PCOS treatment, studies concerning the substance have been, in fact, inconclusive.…”

“…What is more, although inositol has been proposed as a possible PCOS treatment, studies concerning the substance have been, in fact, inconclusive. On the one hand, several meta-analyses have shown a significant improvement in either BMI or WHR in patients with PCOS after treatment with MI [138][139][140]; on the other hand, the meta-analysis performed by Unfer et al showed a reduction in BMI, but not WHR, in patients with PCOS after treatment with MI [142]. In conclusion, despite certain promising indications that there may be a negative relationship between inositol supplementation and ovulatory infertility, the literature data are too conflicting at this point to conclude that its role is appreciatively more beneficial than a placebo.…”

Lean Polycystic Ovary Syndrome: A Narrative Review

“…In PCOS patients, after MYO-INS therapy. BMI, fasting insulin, fasting glucose, HOMA, LH, FSH, estradiol, sex hormone-binding globulin (SHBG), Dehydroepiandrosterone (DHEA), testosterone, anthropometric, metabolic, and endocrine outcomes [45] did not improve significantly. Greff et al [46] conducted a metaanalysis of 26 RCTs incvolving 1691 PCOS patients.…”

“…MYO-INS should be considered experimental in PCOS, according to international guidelines lines [11], and more research is needed. Jethaliya et al [45] conducted a meta-analysis of 17 RCTs involving 1083 PCOS patients. In PCOS patients, after MYO-INS therapy.…”